WILPO (phentermine hydrochloride) by Novartis is obesity, amphetamine (d- and dll-amphetamine). Approved for hypertension.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
WILPO is a phentermine hydrochloride tablet, an oral sympathomimetic amine anorectic indicated for obesity management. It functions as a d- and dl-amphetamine derivative that suppresses appetite and may modulate central nervous system and metabolic effects to reduce weight. The exact primary mechanism of action—whether appetite suppression, CNS effects, or metabolic modulation—remains incompletely established.
As a pre-launch obesity drug from Novartis, roles will focus on launch preparation, market access, and competitive positioning; team size likely scaling ahead of approval.
obesity, amphetamine (d- and dll-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions,…
WILPO represents a pre-launch growth opportunity at Novartis in the high-demand obesity space, but career visibility is currently limited by zero linked job postings. Roles will scale significantly post-approval, with emphasis on commercial execution, payer negotiation, and competitive differentiation against GLP-1 agents.
Worked on WILPO at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.